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Methods: 4988 children at the age from 2 till 5 years having risk factors were included in the program of preventive vaccination with the use of pneumococcal vaccine "Prevenar-13" and influenza vaccine. The assessment of program efficiency is done on the basis of the pneumonia morbidity and mortality monitoring for the period of 2010-2017 on the territory of the Amur region of Russia.
Results: During the year two periods of the morbidity growth were registered: at the 4-7 th weeks and 42-50 th weeks with the peak in March and October. A correlation of annual dynamics of pneumonia morbidity with the level of acute respiratory viral infections (ARVI) (r = 0.89) was revealed. Among patients with pneumonia, adults predominated (72.7 AE 0.34%). But intensive parameters of the morbidity were significantly higher among children and teenagers (1010.9 AE 126.2 per 100000) than among adults (622.3 AE 61.0 per 100000). The disease was more common for children of 0 to 2 years and senior age people (over 65). Among children pneumonia morbidity in the post-vaccination period decreased 2.3 times. For 10 years the number of people vaccinated increased 2.2 times (from 17.5% till 39.7%), and the level of ARVI and influenza got lower by 29.2%. During the period of realization of preventive programs (2013-2017) the level of pneumonia morbidity on the territory of the Amur region decreased by 35.5% and among children by 2.6 times. The mortality decreased by 44.2% and from pneumonia 3.5 times.
Conclusion:
The realization of the regional program of monitoring and prevention of acute respiratory diseases with influenza and pneumococcal vaccines has a high level of medical and social-economic efficiency. Methods: Case outline: We describe the case of bronchiectasis caused by N. farcinica in a 47-year-year-old female patient. She was admitted to our hospital with a two-day history of productive cough and haemoptysis. CT showed bronchial dilatation and inflammation in the middle lobe of right lung and lower lobe of left lung.
Results: Productive cough and haemoptysis did not improve after two-day treatment with Piperacillin-Tazobactam 2.5 g/day. Later, N. farcinica was identified as the responsible organism by 16S rRNA sequencing in sputum and bronchial brush samples, and therefore Piperacillin-Tazobactam therapy was replaced by intravenous TMP-SMX. The patient soon recovered and was discharged from the hospital. Oral TMP-SMX was prescribed as a discharge medication to be used continuously at home.
N. farcinica is a rare infectious agent mainly affecting immunocompromised patients. In any case, a higher index of suspicion is needed, as diagnosis can easily be missed due to the absence of characteristic symptoms and the several difficulties usually encountered in identifying the pathogen. 
Methods: Among patients diagnosed with NC-NB MAC LD between
March 2000 and December 2013, 551 patients who were followed until December 2017 were enrolled at a tertiary referral centre in South Korea. Patients were subdivided into the progressive and stationary group according to whether treatment was started within 3 years from the time of diagnosis. We also investigated the rate of spontaneous sputum conversion in the untreated group.
Results: The mean age of 551 patients was 61.1 years. During the median 5.8 years of follow-up, 323 (58.6%) of the patients received treatment within 3 years (progressive group), whereas remaining 228 (41.4%) patients did not (stationary group). Multivariate analysis revealed that age ≤60 years, a positive sputum smear, the presence of any systemic symptoms and M. intracellulare isolates were predictors of receiving treatment. Moreover, during the median of 5.0 years follow-up, spontaneous sputum conversion occurred in 52.2% patients among those who did not receive treatment. Background and Aims: Nosocomial pneumonia acquired in Intensive Care Unit (ICU) include Hospital Acquired Pneumonia (HA|P) and Ventilator Associated Pneumonia (VAP) will prolong length of stay, increase mechanical ventilation and mortality or either resistance with multidrug. In this study we evaluate correlation between severity of pulmonary infection cases using Acute Physiology and Chronic Health Evaluation II and the pathogen and the impact with mortality and length of stay in ICU.
Conclusion

